GlassScriptPhysician profile
Lance R Varns
NPI 1962583534
$11,059.31
in general payments reported to CMS, 2019-2025
32 companies · $2,690 in 2025
The $2,690 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,393 · 2022: $2,571 · 2023: $2,761 · 2024: $1,643 · 2025: $2,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,722 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,722.16 |
| Education | $372.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,019.14 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,552.74 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,180.95 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $1,018.70 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Boehringer Ingelheim Pharmaceuticals, INC. | $923.74 | 2021-2025 | Ofev, Jascayd |
| Electromed, INC. | $675.23 | 2022-2025 | Smartvest |
| Insmed, INC. | $356.52 | 2021-2025 | Arikayce |
| Baxter Healthcare | $279.26 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Genzyme Corporation | $276.90 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $249.89 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $244.37 | 2023-2025 | Winrevair, Zerbaxa |
| Verona Pharma, INC. | $229.47 | 2025 | Ohtuvayre |
| Inari Medical, INC. | $217.45 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alkermes, INC. | $216.11 | 2021 | |
| Mylan Specialty L.P. | $198.72 | 2021-2024 | Yupelri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $190.42 | 2023-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $162.10 | 2021-2025 | Dupixent |
| Amgen INC. | $147.72 | 2021-2025 | Tezspire |
| Galvanize Therapeutics, INC | $145.00 | 2023 | Aliya System |
| Philips North America LLC | $134.60 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.28 | 2024-2025 | Glassia |
| Janssen Pharmaceuticals, INC | $94.46 | 2021 | |
| Genentech USA, INC. | $71.23 | 2024-2025 | Xolair |
| Pfizer INC. | $61.68 | 2023 | |
| Advanced Respiratory, INC | $34.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.81 | 2023 | |
| Viatris Specialty LLC | $32.18 | 2025 | Yupelri |
| Pulmonx Corporation | $23.40 | 2023 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Jazz Pharmaceuticals INC. | $20.66 | 2025 | |
| Liquidia Technologies, INC. | $20.46 | 2025 | Yutrepia |
| Pinnacle Biologics, INC | $17.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Varns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.